Фармакология взаимодействия регуляторных пептидных систем головного мозга в механизмах подкрепления

Landgren, S. Association of Pro-Ghrelin and GHSR1A gene polymorphisms and haplotypes with heavy alcohol use and body mass. /Landgren, S., Jerlhag, E., Zetterberg, H., Gonzalez-Quintela, A., Campos, J., Olofsson, U., Nilsson, S., Blennow, K., Engel, J.A. // Alcoholism – Clinical and Experimental Research 32 (12) – 2008 – Р.2054–2061.

Landgren, S. Genetic variation of the ghrelin signaling system in females with severe alcohol dependence. /Landgren, S., Jerlhag, E., Hallman, J., Oreland, L., Lissner, L., Strandhagen, E., Thelle, D.S., Zetterberg, H., Blennow, K., Engel, J.A. // Alcoholism –Clinical and Experimental Research 34 (9) – 2010 – Р.1519–1524.

Larsson, A. Neurochemical and behavioral studies on ethanol and nicotine interactions. /Larsson, A., Engel, J.A. // Neuroscience and Biobehavioral Reviews 27 (8) – 2004 – Р.713–720.

Larsson, A. Voluntary ethanol intake increases extracellular acetylcholine levels in the ventral tegmental area in the rat. /Larsson, A., Edstrom, L., Svensson, L., Soderpalm, B., Engel, J.A. // Alcohol and Alcoholism 40 (5) – 2005 – Р.349–358.

Laviolette S.R. GABAA receptors in the ventral tegmental area control bidirectional reward signalling between dopaminergic and non-dopamingeric neural motivational systems. /Laviolette S.R., van der Kooy D. // Eur. J. Neurosci. 2001. V.13. P.1009–1015.

Le Doux J.E. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. /Le Doux J.E., Iwata J., Cicchetti P., Reis D.J. // J. Neurosci 1988; 8:2517–2529.

Lelas S. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. /Lelas S., Wong H., Li Y.W. et al. // J. Pharmacol. Exp. Ther. 2004. V. 309. P.293–302.

Lewis K. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. /Lewis K., Li C., Perrin M.H. et al. // Proc. Natl. Acad. Sci. USA. 2001. V. 98. P.7570–7575.

Li Y.W. Receptor occupancy of nonpeptide corticotropinreleasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. /Li Y.W., Hill G., Wong H. et al. // J. Pharmacol. Exp. Ther. 2003. V. 305. P.86–96.

Li, Y. Hypocretin/Orexin exites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. /Y. Li, X. B. Gao, T. Sakurai et al. // Neuron. – 2002. – Vol. 36. – P.1169–1181.

Li, Y. Orexin in the midline thaiamus are involved in the expression of conditioned place aversion to morphine withdrawal. /Y. Li, H. Wang, K. Qi et al. // Physiology and Behavior. – 2011 – Vol.102. – P.42–50.

Liaw C.W. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. /Liaw C.W., Lovenberg T.W., Barry G. et al. // Endocrinology. 1996. V. 137. P.72–77.

Lin, L. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin receptor 2 gene. /L. Lin, J. Faraco, R. Li et al. // Cell. – 1999. – Vol.98. – P.365–376.

Liu, Z. W. Adenosine inhibits activity of hypocretin/orexin neurons by the Al receptor in the lateral hypothalamus: a possible sleep-promoting effect. /Z. W. Liu, X. B. Gao. // J. Neurophysiol. – 2007. – Vol.97. – P.837–848.

Löf, E. Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. /Olausson, P., deBejczy, A., Stomberg, R., McIntosh, J.M., Taylor, J.R., Soderpalm, B. // Psychopharmacology (Berl) 195 (3) – 2007 – Р.333–343.

Lovenberg T.W. CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. /Lovenberg T.W., Chalmers D.T., Liu C., De Souza E.B. // Endocrinology. 1995. V. 136. P.4139–4142.

Lu, X. Y. Differential distribution and regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting. /X. Y. Lu, D. Bagnol, S. Burke et al. // Horm. Behav. –2000. – Vol.37. – P.1529–1533.

Lutter M. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. / Lutter M., Sakata I., Osborne-Lawrence S., Rovinsky S.A., Anderson J.G., et al.// Nat Neurosci. 2008; 11:752–753. [PubMed]

Marcus, J. N. Differential expression of orexin receptors 1 and 2 in the rat brain. /J. N. Marcus, C. G. Aschkenasi, C. E. Lee et al. // J. Comp. Neurol. – 2001. – Vol.435. – P.6–25.

Martin G. Interaction of the hypocretins with neurotransmitters in the nucleus accumbens. / Martin G., Fabre V., Siggins G.R., de Lecea L. // RegulPept. 2002; 104:111–7. [PubMed]

Matsuki, T. Selective loss of GABA (B) receptors in orexin-producing neurons results in disrupted sleep/wakefulness architecture. /T. Matsuki, M. Nomiyama, H. Takahira et al. // Proc. Nail. Acad. Sci. USA. – 2009. – Vol.106. – P.4459–4464.

McKee, S.A. Varenicline reduces alcohol self-administration in heavy-drinking smokers. /McKee, S.A., Harrison, E.L., O’Malley, S.S., Krishnan-Sarin, S., Shi, J., Tetrault, J.M., Picciotto, M.R., Petrakis, I.L., Estevez, N., Balchunas, E. // Biological Psychiatry 66 (2) – 2009 – Р.185–190.

Menzaghi F. Characterization of a novel and potent corticotropinreleasing factor antagonist in rats. /Menzaghi F., Howard R.L., Heinrichs S.C. et al // J. Pharmacol. Exp. Ther. 1994. V. 269. P.564–572.

Merali Z. Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala. /Merali Z., McIntosh J., Kent P. et al. // J. Neurosci. 1998. V. 18. P.4758–4766.

Merlo Pich E. Corticotropin-releasing factor release from the mediobasal hypothalamus of the rat as measured by microdialysis. /Merlo Pich E., Koob G.F., Heilig M. et al. // Neuroscience. 1993. V. 55. P.695–707.

Mokrosinski, J. Modulation of the constitutive activity of the ghrelin receptor by use of pharmacological tools and mutagenesis. /Mokrosinski, J., Holst, B. // Methods in Enzymology484 – 2010 – Р.53–73.

Moreau J.L. Urocortin, a novel neuropeptide with anxiogenic-like properties. /Moreau J.L., Kilpatrick G., Jenck F. // NeuroReport. 1997. V. 8. P.1697–1701.

Mozid A.M. Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. / Mozid A.M., Tringali G., Forsling M.L., Hendricks M.S., Ajodha S., et al. // HormMetab Res. 2003;35:455–459. [PubMed]

Myers R.D. Anatomical “circuitry” in the brain mediating alcohol drinking revealed by THP-reactive sites in the limbic system. /Myers R.D. // Alcohol 1990;7:449–459.

Naleid, A.M. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. /Naleid, A.M., Grace, M.K., Cummings, D.E., Levine, A.S. // Peptides 26 (11) – 2005 – Р.2274–2279.

Nambu, T. Distribution of orexin neurons in the adult rat brain. /T. Nambu, T. Sakurai, K. Mizukami et al. // Brain Res. – 1999 – Vol.827. – P.243–260.

Napier T.C. Opiod modulation of ventral pallidal inputs. /Napier T.C., Mitrovic I. // Ann. N.Y. Acad. Sci. 1999. V.87. P.176–201.

Nemeroff C.B. New vistas in neuropeptide research in neuropsychiatry: focus on corticotropin-releasing factor. /Nemeroff C.B. // Neuropsychopharmacology. 1992. V. 6. P.69–75.

Nestler E.J. Is there a common molecular pathway for addiction? /Nestler E.J. // Nat Neurosci 2005;8:1445–1449.

Nicola S.M. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. /Nicola S.M., Surmeier J., Malenka R.C. // Annu. Rev. Neurosci. 2000. V.23. P.185–215.

Nijsen M.J. The role of the CRH type 1 receptor in autonomic responses to corticotropin-releasing hormone in the rat. /Nijsen M.J., Croiset G., Stam R. et al. // Neuropsychopharmacology. 2000. V. 22. P.388–399.

O’Donnell P. Dopamine gating of forebrain neural ensembles. /O’Donnell P. // Eur. J. Neurosci. 2003. V.17. P.429–435.

Okuyama S. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. /Okuyama S., Chaki S., Kawashima N. et al. // J. Pharmacol. Exp. Ther. 1999. V. 289. P.926–935.

Olds J. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. /Olds J, Milner P. // J Comp Physiol Psychol 1954; 47:419–427. [PubMed: 13233369]

Olds J. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. /Olds J., Milner P. // J Comp Physiol Psychol. 1954; 47:419–27. [PubMed]

Olszewski, P.K. Hypothalamic paraventricular injections of ghrelin: effect on feeding and c-Fos immunoreactivity. /Olszewski, P.K., Grace, M.K., Billington, C.J., Levine, A.S. // Peptides 24 (6) – 2003a – Р.919–923.

Olszewski, P.K. Neural basis of orexigenic effects of ghrelin acting within lateral hypothalamus. /Olszewski, P.K., Li, D.H., Grace, M.K., Billington, C.J., Kotz, C.M., Levine, A.S. // Peptides 24 (4) – 2003b – Р.597–602.

Patterson Z.R. Altered metabolic and neurochemical responses to chronic unpredictable stressors in ghrelin receptor-deficient mice. /Patterson Z.R., Ducharme R, Anisman H, Abizaid A. // Eur J Neurosci. 2010; 32:632–639. [PubMed]

Perello M. Functional implications of limited leptin receptor and ghrelin receptor co-expression in the brain. / Perello M, Scott MM, Sakata I, Lee CE, Chuang JC, et al. // J Comp Neurol 2011 [PMC free article] [PubMed]

Perello M. Ghrelin increases the rewarding value of high-fat diet in an orexin-dependent manner /Perello M., Sakata I., Birnbaum S., Chuang J.C., Osborne-Lawrence S., Rovinsky, S.A., Woloszyn, J., Yanagisawa, M., Lutter M., Zigman J.M. // Biol. Psychiat. 2010. V. 67, №9. P. 880–886.

Perello, M. Ghrelin increases the rewarding value of high-fat diet in an orexin-dependent manner. /Perello, M., Sakata, I., Birnbaum, S., Chuang, J.C., Osborne-Lawrence, S., Rovinsky, S.A., Woloszyn, J., Yanagisawa, M., Lutter, M., Zigman, J.M., 2010. // BiologicalPsychiatry 67 (9), 880–886.

Perrin M.H. Cloning and functional expression of a rat brain corticotrophin releasing factor (CRF) receptor. /Perrin M.H., Donaldson C.J., Chen R. et al. // Endocrinology. 1993. V. 133. P.3058–3061.

Pettit H.O. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. /Pettit H.O., Ettenberg A., Bloom F.E., Koob G.F. // Psychopharmacology 1984;84:167–173.

Peyron, C. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. /C. Peyron, J. Faraco, W. Rogers et al. // Natural Medicine. – 2000 – Vol.6. – P.991–997.

Peyron, C. Neurons containing hypocretin (orexin) project to multiple neuronal systems. /C. Peyron, D. K. Tighe, A. N. Van den Pol et al. // J. Neurosci. – 1998 – Vol.18. – P.9996–10015.

Piazza P.V. The role of stress in drug self-administration. /Piazza P.V., Le Moal M. // Trends Pharmacol. Sci. 1998. V. 19. P.67–74.

Potter E. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. /Potter E., Sutton S., Donaldson C. et al. // Proc. Natl. Acad. Sci. USA. 1994. V. 91. P.8777–8781.

Price D.D. Central neural mechanisms that interrelate sensory and affective dimensions of pain. Mol Interv 2002; 2:392–403. [PubMed: 14993415]

Quarta, D. Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens. /Quarta, D., Di Francesco, C., Melotto, S., Mangiarini, L., Heidbreder, C., Hedou, G. // NeurochemistryInternational 54 (2) – 2009 – Р.89–94.

Rassnick S. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. /Rassnick S, Heinrichs SC, Britton KT, Koob GF. // Brain Res 1993a; 605:25–32. [PubMed: 8467387]

Reyes T.M. Categorically distinct acute stressors elicit dissimilar transcriptional profiles in the paraventricular nucleus of the hypothalamus. /Reyes T.M., Walker J.R., DeCino C., Hogenesch J.B., Sawchenko P.E. // J Neurosci. 2003; 23:5607–16. [PubMed]

Robinson, T.E. The neural basis of drug craving – an incentivesensitization theory of addiction. /Robinson, T.E., Berridge, K.C. // Brain Research Reviews 18 (3) – 1993 – Р.247–291.

Rosin, D. L. Hypothalamic orexin (hypocretin) neurons express vesicular glutamate transporters VGLUT1 or VGLUT2. /D. L. Rosin, M C. Weston, C. P. Sevigny et al. // J. Comp. Neurol. − 2003 − Vol.465, − P.593–603.

Sakurai, T. Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. /T. Sakurai, A. R. Nagata, A. Yamanaka et al. // Neuron. − 2005 − Vol.46, − P.297–308.

Sakurai, T. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. /T. Sakurai, A. Amemiya, M. Ishii et al. // Cell. −1998 − Vol.92, − P.573–585.

Sarnyai Z. The role of corticotropinreleasing factor in drug addiction. /Sarnyai Z., Shaham Y., Heinrichs S.C. // Pharmacol. Rev. 2001. V. 53. P.209–243.

Schulz W. Multiple reward signals in the brain. /Schulz W. // Nat. Rev. Neurosci. 2000. V.1. P.199–207.

Schuster C.R. Self administration and behavioral dependence on drugs. /Schuster C.R., Thompson T. // Ann Rev. Pharmacol. Toxicol. 1969; 9:483–502.

Seyler L.E. The effects of smoking on ACTH and cortisol secretion. /Seyler L.E., Fertig J., Pomerleau O. et al. / Life Sci. 1984. V. 34. P.57–65.

Shabanov P.D. Extrahypothalamic corticoliberin receptors regulate the reinforcing effects of self-stimulation. /Shabanov P.D., Lebedev A.A., Nozdrachev A.D. // Dokl. Biol. Sci. 406 : 14–17. 2006.

Shabanov P.D. The extended amygdala CRF receptors regulate the reinforcing effect of self-stimulation. /Shabanov P.D. // Int. J. Addiction Res. 1 (1): 200–204. 2008.

Shizgal P. Forebrain neurons driven by rewarding stimulation of the medial forebrain bundle in the rat: comparison of psychophysical and electrophysiological estimates of refractory periods. /Shizgal P., Schindler D., Rompre P.P. // Brain Res. 1989. V.499. P.234–248.

Shizgal P. Neural basis of utility estimation. /Shizgal P. // Curr. Opin. Neurobiol. 1997. V.7. P.198–208.

Shizgal P. On the neural computation of utility. /Shizgal P., Conover K. // Curr. Dir. Psychol. Sci. 1996. V.5. P.37–43.

Shizgal P. Toward a cellular analysis of intracranial self-stimulation: contributions of collision studies. /Shizgal P. // Neurosci. Biobehav. Rev. 1989. V.13. P.81–90.

Skibicka, K.P. Ghrelin and food reward, what’s underneath: the story of potential underlying substrates. /Skibicka, K.P., Dickson, S.L. // Peptides; Special Issue on Ghrelin, in press.

Skibicka, K.P. Ghrelin directly targets the mesolimbic pathway to increase food motivation. /Skibicka, K.P., Hansson, C., Alvarez-Crespo, M., Friberg, A., Dickson, S.L. // Neuroscience, in press-b, (Epub ahead of print) doi:10.1016/j.neuroscience.2011.02.016.

Skibicka, K.P. Role of ghrelin in food reward: impact of ghrelin on sucrose self-administration and mesolimbic dopamine and acetylcholine receptor gene expression. /Skibicka, K.P., Hansson, C., Egecioglu, E., Dickson, S.L. // Addiction Biology, in press-a (Epub ahead of print). doi:10.1111/j.1369-1600.2010.00294.x.

Smith S.M. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. / Smith S.M., Vale W.W. // Dialogues ClinNeurosci. 2006;8:383–395. [PMC free article] [PubMed]

Smith, R. J. Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. /R. J. Smith, G. Aston-Jones // Eur. J. Neuroscience. − 2012 − Vol.35, − P.798–804.

Smith, R. J. Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine- seeking. /R. J. Smith, G. Aston-Jones, E. R. See // Eur. J. Neuroscience. − 2009b − Vol.30, − P.493–503.

Specio S.E. CRF1 receptor antagonists attenuate escalated cocaine self-administration in rats. /Specio SE, Wee S, O’Dell LE, Boutrel B, Zorrilla EP, Koob GF. // Psychopharmacology 2008; 196:473–482.

Stam R. Long-lasting stress sensitization. /Stam R., Bruijnzeel A.W., Wiegant V.M. // Eur. J. Pharmacol. 2000. V. 405. P.217–224.

Steensland, P. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. /Steensland, P., Simms, J.A., Holgate, J., Richards, J.K., Bartlett, S.E. // Proceedings of the National Academy of Sciences of the United States of America 104 (30) – 2007 – Р.12518–12523.

Stevanovic D. The effect of centrally administered ghrelin on pituitary ACTH cells and circulating ACTH and corticosterone in rats. / Stevanovic D., Milosevic V., Starcevic V.P., Severs W.B. // Life Sci. 2007;80:867–872. [PubMed]

Stricker-Krongrad A. Modulation of hypothalamic hypocretin/orexin mRNA expression by glucocorticoids. / Stricker-Krongrad A., Beck B. // BiochemBiophys Res Commun. 2002; 296:129–33. [PubMed]

Sutton R.E. Corticotropin releasing factor produces behavioural activation in rats. /Sutton R.E., Koob G.F., Le Moal M. et al. // Nature. 1982. V. 297. P.331–333.

Suzanne L. Dickson. The role of central ghrelin system in reward from food and chemical drugs. /SuzanneL.Dickson, Emil Egecioglu, Sara Landgren. // Molecular and Cellular Endocrinology 340 – 2011 – Р.80-87.

Swanson L.W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. /Swanson L.W., Sawchenko P.E., Rivier J., Vale W.W. // Neuroendocrinology. 1983. V. 36. P.165–186.

Swerdlow N.R. Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. /Swerdlow N.R., Geyer M.A., Vale W.W., Koob G.F. // Psychopharmacology (Berl.). 1986. V.88. P.147–152.

Takahashi L.K. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. /Takahashi L.K., Kalin N.H., Vanden Burgt J.A., Sherman J.E. // Behav. Neurosci. 1989. V. 103. P.648–654.

Tessari, M. Correlation between serum ghrelin levels and cocaine-seeking behaviour triggered by cocaine-associated conditioned stimuli in rats. /Tessari, M., Catalano, A., Pellitteri, M., Di Francesco, C., Marini, F., Gerrard, P.A., Heidbreder, C.A., Melotto, S. // Addiction Biology 12 (1) – 2007 – Р.22–29.

Thannickal, T. C. Reduced number of hypocretin neurons in human narcolepsy. /T. C. Thannickal, R. Y. Moore, R. Nienhius et al. // Neuron. – 2000. – Vol. 27. – P.469–474.

Triverdi, P. Distribution of orexin receptor mRNA in the rat brain. /P. Triverdi, H. Yu, D. J. MacNeil et al. // FEBS Lett. –1998. – Vol.438. – P.71–75.

Tschöp, M. Ghrelin induces adiposity in rodents. /Tschöp, M., Smiley, D.L., Heiman, M.L. // Nature 407 (6806) – 2000 – Р.908–913.

Tschöp, M. Post-prandial decrease of circulating human ghrelin levels. /Tschöp, M., Wawarta, R., Riepl, R.L., Friedrich, S., Bidlingmaier, M., Landgraf, R., Folwaczny, C. // Journal of Endocrinological Investigation 24 (6), 2001, Rc19–Rc21.

Tsujino, N. Cholecystokinin activates orexin/hypocretin neuronos through the cholecystokinin A receptor. /N. Tsujino, A. Yamanaka, K. Ichiki et al. // J. Neurosci. – 2005. – Vol.25. – P.7459–7469.

Tsunematsu, T. Vasopressin increases locomotion through a V1a receptor in orexin/hypocretin neurons: Implication for water homeostasis. /T. Tsunimatsu, L.Y. Fu, A. Yamanaka et al. // J. Neurosci. – 2008. – Vol.28. – P.228–238.

Tung Y.L. Glucocorticoid-dependent stimulation of adiposity and appetite by a ghrelin mimetic in the rat. /Tung Y.L., Hewson A.K., Dickson S.L. // Eur J Endocrinol. 2004;150:905–911. [PubMed]

Vaccarino F.J. Blockade of nucleus accumbens opiate receptors attenuates intravenous heroin reward in the rat. / Vaccarino F.J., Bloom F.E., Koob G.F. // Psychopharmacology 1985;86:37–42.

Vale W. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. /Vale W., Spiess J., Rivier C., Rivier J. // Science. 1981. V. 213. P.1394–1397.

Van Gaalen M.M. Reduced attention in mice overproducing corticotropin-releasing hormone. /Van Gaalen M.M., Stenzel-Poore M., Holsboer F., Steckler T. // Behav. Brain Res. 2003. V. 142. P.69–79.

Waraczynski M. Basal forebrain knife cuts and medial forebrain bundle self-stimulation. /Waraczynski M. // Brain Res. 1988. V.438. P.8–22.

Waraczynski M. Failure of amygdaloid lesions to increase the thresold for self-stimulation of the lateral hypothalamus and ventral tegmental area. /Waraczynski M., Cheong Ton M.N., Shizgal P. // Behav. Brain Res. 1990. V.40. P.159–168.

Waraczynski M. Lesions of pontomesencephalic cholinergic nuclei do not substantially disrupt the reward value of medial forebrain bundle stimulation. /Waraczynski M., Perkins M. // Brain Res. 1998. V.800. P.154–169.

Waraczynski M. Lidocaine inactivation demonstrates a stronger role for central versus medial extended amygdala in medial forebrain bundle selfstimulation. /Waraczynski M. // Brain Res. 2003. V.962. P.180–198.

Waraczynski M. Midbrain periaqueductal lesions do not degrade medial forebrain bundle stimulation reward. /Waraczynski M., Carlton E., Perkins M. // Behav. Brain Res. 1998. V.95. P.167–177.

Waraczynski M. Reward saturation in medial forebrain bundle self-stimulation. /Waraczynski M., Stellar J.R., Gallistel C.R. // Physiol. Behav. 1987. V.41. P.585–593.

Waraczynski M. Self-stimulation of the MFB following parabrachial lesions. /Waraczynski M., Shizgal P. // Physiol. Behav. 1995. V.58. №3. P.559–566.

Waraczynski M. Temporary inactivation of the retrorubral fields decreases the rewarding effect of medial forebrain bundle stimulation. /Waraczynski M., Perkins M. // Brain Res. 2000. V.885. P.154–165.

Waraczynski M.A. The central extended amygdale network as a proposed circuit underlying reward valuation. /Waraczynski M.A. // Neurosci. Biobehav. Rev. 2005. V.28. P. 1–25.

Weiss F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. /Weiss F., Markou A., Lorang M.T., Koob G.F. // Brain Res 1992;593:314–318.

Weiss F. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. /Weiss F., Ciccocioppo R., Parsons L.H. et al. // Ann. N. Y. Acad. Sci. 2001. V. 937. P.1–26.

Wellman, P.J. Augmentation of cocaine hyperactivity in rats by systemic ghrelin. /Wellman, P.J., Davis, K.W., Nation, J.R. // Regulatory Peptides 125 (1–3), 2005151–154.

Wilkins J.N. Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers. /Wilkins J.N., Carlson H.E., Van Vunakis H. et al. // Psychopharmacology (Berl.). 1982. V. 78. P.305–308.

Winsky-Sommerer R. Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. /Winsky-Sommerer R., Yamanaka A., Diano S., Borok E., Roberts A.J., Sakurai T., Kilduff T.S., Horvath T.L., de Lecea L // J Neurosci. 2004;24:11439–48.

Wren A.M. The hypothalamic mechanisms of the hypophysiotropic action of ghrelin. / Wren A.M., Small C.J., Fribbens C.V., Neary N.M., Ward H.L., et al. // Neuroendocrinology. 2002;76:316–324. [PubMed]

Wren, A.M. Ghrelin causeshyperphagia and obesity in rats. /Wren, A.M., Small, C.J., Abbott, C.R., Dhillo, W.S., Seal, L.J., Cohen, M.A., Batterham, R.L., Taheri, S., Stanley, S.A., Ghatei, M.A., Bloom, S.R. // Diabetes 50 (11), 2001b. Р. 2540–2547.

Wren, A.M. Ghrelin enhances appetite and increases food intake in humans. /Wren, A.M., Seal, L.J., Cohen, M.A., Brynes, A.E., Frost, G.S., Murphy, K.G., Dhillo, W.S., Ghatei, M.A., Bloom, S.R. // Journal of Clinical Endocrinology and Metabolism 86 (12), 2001a. Р.5992–5995.

Wren, A.M. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. /Wren, A.M., Small, C.J., Ward, H.L., Murphy, K.G., Dakin, C.L., Taheri, S., Kennedy, A.R., Roberts, G.H., Morgan, D.G.A., Ghatei, M.A., Bloom, S.R. // Endocrinology 141 (11), 2000. Р.4325–4328.

Wurst, F.M. Gender differences for ghrelin levels in alcohol-dependent patients and differences between alcoholics and healthy controls. /Wurst, F.M., Graf, I., Ehrenthal, H.D., Klein, S., Backhaus, J., Blank, S., Graf, M., Pridzun, L., Wiesbeck, G.A., Junghanns, K. // Alcoholism – Clinical and Experimental Research 31 (12), 2007. 2006–2011.